Figure 3.
Circulating tumor DNA (ctDNA) detection rates in tumor‐related parameters of breast cancer patients after excluding clonal hematopoiesis (CH)‐associated variants. A, Breast cancer disease stage. B, Multiple mutations detection rate. C, Tumor size, nodal status and metastases status. P‐values were calculated using χ2 2‐sided test of independence. Disease staging follows the American Joint Committee on Cancer (AJCC) TNM staging criteria for non‐metastatic disease patients. ctDNA detection rates shown after excluding CH‐associated variants. Number of patients shown below each corresponding bar. Stage II and stage III breast cancer patients were combined into a single group due to small sample size